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Title: Induced Modifications to the Tumor Microenvironment Via Micellar Drug Delivery Systems 
as a Mode of Cancer Treatment 
 
Abstract: About 40% of patients with non–small cell lung cancer (NSCLC) have stage IV cancer 
at the time of diagnosis, correlating to only a 7% five-year survival rate. Similarly, triple negative 
breast cancer (TNBC) has a high rate of diagnosis at stage IV, with a 22% five-year survival 
rate. The only viable treatment options for metastatic disease are systemic chemotherapy and 
immunotherapy. Nonetheless, chemoresistance remains a major cause of chemotherapy 
failure. New immunotherapeutic modalities such as anti– PD-1 immune checkpoint blockade 
have shown promise; however, response to such strategies is highly variable across patients. 
Here, we show that our unique poly(2-oxazoline)–based nanomicellar formulation (PM) of 
Resiquimod, an imidazoquinoline Toll-like receptor (TLR) 7/8 agonist, had a superior tumor 
inhibitory effect in a metastatic model of lung adenocarcinoma, relative to anti–PD-1 therapy or 
platinum-based chemotherapy. We also begin to investigate the capability of SB525334 PM, a 
transforming growth factor beta receptor (TGFBR) inhibitor, to inhibit a model of mammary 
carcinoma. Investigation of the in vivo immune status following Resiquimod PM treatment 
showed that Resiquimod-based stimulation of antigen-presenting cells in the tumor 
microenvironment resulted in the mobilization of an antitumor CD8+ immune response. Our 
study demonstrates the promise of poly(2-oxazoline)-formulated Resiquimod for treating 
metastatic NSCLC, and provides new directions for SB525334 formulations. 
 
1. Introduction 
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Cancer is the 2nd leading cause of death in the United States and a top-ten leading 
cause globally1. Chemotherapeutic drugs are commonly prescribed as treatment for several 
types of cancer; however, viable therapy options are still limited for many diagnoses once 
metastasis has begun. Two such malignancies include non-small cell lung cancer (NSCLC) and 
triple- negative breast cancer (TNBC). NSCLC is the most frequently diagnosed lung 
malignancy, constituting 80-85% of lung cancers, and accounts for the majority of cancer 
related deaths worldwide2. While TNBC only accounts for 10-20% of breast cancer cases, it is 
estimated to account for over 30% of breast cancer deaths3. Postsurgical recurrence with 
ensuing metastasis is a primary cause of mortality in a large proportion of both NSCLC and 
TNBC cases4. Recent studies indicate that over half of advanced lung adenocarcinomas may 
possess a therapeutically targetable driver mutation, with additional predictive biomarkers 
expected in the near future5,6. While such advancements have paved the way for targeted 
therapeutics, the benefits of these interventions are often fleeting due to the development of 
chemoresistance, primarily stemming from tumor-host interactions (THI)2. The development of 
treatment regimes that target the tumor microenvironment (TME) is therefore crucial for 
mitigating the effect of THI and managing advanced NSCLC. 
U.S. Food and Drug Administration (FDA) approval of immune checkpoint blockade 
therapy has reshaped the landscape of both NSCLC and TNBC treatment. Programmed death 
1, more commonly known as PD-1, is an immune checkpoint protein expressed on T cells to 
regulate self-tolerance by inhibiting autoimmunity. Interaction of PD-1 with its cognate ligand, 
PD-L1, commonly expressed on macrophages and myeloid cells, generates negative feedback 
to inhibit T cell activation. Certain cancers overexpress PD-L1 to benefit from PD-1/PD-L1 axis–
mediated suppression of adaptive immunity7. The use of antibodies against PD-1 has shown a 
favorable outcome in cancers with a high expression of PD-L18. However, only a 
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minority of PD-L1–positive patients with either NSCLC or TNBC respond to anti–PD-1 therapy 
due, in part, to intratumoral and temporal heterogeneity of pathologically regulated PD-L1 
expression, underscoring the role of the pathophysiological state of the tumor microenvironment 
in dictating treatment response to anti–PD-1 therapy9,10. 
Advances have been made in understanding the paradoxical role of immune cells in 
cancer. Signaling interactions between cancer cells and neighboring immune cells lead to the 
protumorigenic evolution of the latter, yielding cells that lack antitumor properties11. For 
instance, a large proportion of the tumor-associated macrophages (TAMs) display an 
alternatively activated endotype, which causes a shift in the T helper 1 (TH1)/TH2 cytokine 
balance toward a more TH2-like (anti-inflammatory) activity, resulting in an immunosuppressive 
niche conducive to tumor growth12. In addition, TAMs can dampen the adaptive immune 
response by impeding the tumor infiltration of CD8+ cytotoxic T cells13. Of note, cancers 
deficient in tumor-penetrating T lymphocytes (“cold tumors”) are refractory to immunotherapy14. 
Therefore, treatment strategies aimed at stimulating the T cell immune response are essential 
for a durable antitumor effect. Cancer associated fibroblasts (CAFs) can also modulate the 
endotype of T cells and TAMs, with late stage, metastatic tumor site CAFs typically promoting 
anti- inflammatory differentiation15. In addition, CAFs of such tumors can promote the growth of 
tumors through increased angiogenesis, chemoresistance, and desmoplasticity16,17. 
Recently, the tumor microenvironment (TME), a multicellular system surrounding the tumor 
mass composed of immune cells, dendritic cells, and vasculature among other things, has 
become a targeted treatment site for stimulating antitumor immune responses.
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Toll-like receptor (TLR) agonists are a class of immune-stimulating agents that have 
shown promising immune-enhancing effects in both human and animal models of cancers18. 
Expressed primarily on innate immune cells, TLRs are transmembrane proteins that recognize 
pathogen-associated molecular patterns (PAMPs), which makes them an indispensable part of 
the innate and adaptive immunity. Transforming growth factor beta (TGFβ) inhibitors are a class 
of small molecules that prevent TGFβ receptors 1 and/or 2 from binding to their cognate ligand. 
Abundantly expressed within the TME, TGFβ can promote epithelial to mesenchymal transitions 
(EMT), promoting cell invasion and metastisis in late stage cancers19,20. To date, imiquimod 
(Aldara; Graceway Pharmaceuticals; TLR 7 agonist) is the only TLR agonist approved by the 
FDA, and no TGFβR inhibitor has completed clinical trials. Many previously proposed 
therapeutics of TLR7/8 and TGFβ have failed in clinical trials, largely owed to the poor 
pharmacokinetics as translated from model organisms to humans. Imiquimod is administered 
topically as a 5% (50 mg/g) cream for the treatment of superficialbasal cell carcinoma, 
precancerous actinic keratoses, and genital and perianal warts21,22. Topical administration, 
however, is not feasible for cancers that are not accessible from the 
skin. Poor solubility of small-molecule TLR ligands and TGFβR inhibitors prevent their 
systemic delivery to distal tumors and metastatic sites, and therefore, efficient delivery 
systems are warranted18. 
The present study investigates the immunotherapeutic potential of intravenously 
administered, poly(2-oxazoline) (POx)–based nanomicellar formulation of Resiquimod 
(Resiquimod PM), a TLR 7/8 agonist chemically related to imiquimod, in a clinically relevant 
mouse model of metastatic NSCLC. Following work begins to investigate the 
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antitumor capabilities of POx-based nanomicellar formulations of SB525334, an inhibitor of TGFβ 
receptor 1, in a highly invasive and metastatic-prone mouse model of TNBC. POx is an 
amphiphilic triblock copolymer composed of one hydrophobic block of poly(2- butyl-2- oxazoline) 
(BuOx) flanked by two hydrophilic blocks of (2-methyl2-oxazoline) (MeOx). POx micelles exhibit 
an exceptionally high solubilization capacity for water- insoluble drugs in single drug– and 
multidrug-loaded variations23,24. We leveraged the characteristic sub–100-nm size of POx 
micelles to increase the distribution of the TLR agonist and TGFβR1 inhibitor by passive 
targeting to the tumor. Furthermore, we also evaluated the anticancer efficacy of established 
frontline therapies for NSCLC and TNBC, including immune checkpoint blockade therapy and 
platinum-based chemotherapy in combination with chemosensitizers, in the same models of 
NSCLC, with plans to evaluate the effect in the same models of TNBC. 
 
2. Materials and Methods 
 
 
Triblock copolymer of P[MeOx35-b-BuOx34-b-MeOx35]-piperazine [Mn (number-
average molecular weight) = 13 kDa, Mw (weight- average molecular weight)/Mn = 1.14] was 
synthesized by living cationic ring-opening polymerization of 2-oxazolines as described 
previously25. 1H nuclear magnetic resonance spectrum was obtained using a Bruker Avance 
III 400-MHz spectrometer and analyzed using the MestReNova (11.0) software. The molecular 
weight distribution of the polymer was measured by gel permeation chromatography on a 
Viscotek VE2001 solvent sampling module. The alkylated prodrug of cisplatin (C6CP) was 
synthesized as described previously26. Resiquimod and SB525334 were purchased from 
APExBIO (no. B1054, no. A5602), and Rat IgG2a, κ anti-mouse PD-1, RMP1-14 clone was 
purchased from BioXCell (no. BE0146). All other reagents were purchased from Sigma-Aldrich 
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and Fisher Scientific. 
 
2.1 POx micelle preparation and characterization 
 
POx micelles were prepared by the thin-film hydration method. The polymer and drugs 
(Resiquimod, C6 cisplatin prodrug, PTX, AZD7762, VE-822, AZD8055, SB525334, SB505124, 
and LY2109761) were dissolved in a common solvent and subjected to mild heating (45°C) 
accompanied by constant nitrogen flow for complete removal of solvent to form a dried thin 
film. The thin film was subsequently hydrated with saline at the optimal temperature (room 
temperature for Resiquimod PM, 50°C for SB525334, SB505124, and LY2109761, and 55°C for 
C6CP/AZD7762, C6CP/VE-822, C6CP/AZD8005, and PTX/VE-822 PMs) to produce drug-
loaded micelles. 
The drug amount incorporated in the micelles was measured by reversed-phase high- 
pressure liquid chromatography on an Agilent 1200 HPLC system equipped with ChemStation 
software using a Nucleosil C18, 5-μm particle size column [L × inner diameter (ID) 25 cm by 
4.6 mm]. The ultraviolet chromatograms of drugs were obtained using isocratic elution mode 
with a mobile phase of acetonitrile (ACN)/water 60/40 (v/v) and 0.1% trifluoroacetic acid, 
operated at a flow rate of 1 ml/min and a column temperature of 40°C. The micelle samples 
were diluted 50 times with the mobile phase, and an injection volume of 10 μL was used for all 
the samples. The drug loading capacity and loading efficiency of the POx micelles were 
calculated as described previously23. 
The size distribution of POx micelles was determined using the DLS technique on a 
Zetasizer Nano ZS (Malvern Instruments Ltd., UK). Each sample was diluted 10 times with 
normal saline to a final polymer concentration of 1 g/liter, and the intensity-weighted Z average 
size was recorded for three measurements of each sample at a detection angle of 173° and a 
temperature of 25°C. The POx micelles were further characterized by TEM. A high-resolution 
JEOL 2010F FasTEM-200 kV with a Gatan charge-coupled device camera was used for image 
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acquisition. Diluted solutions of POx micelles were dropped onto the TEM grid and allowed to 
dry and stained with 1% uranyl acetate for 2 min before TEM imaging. 
2.2 Cell study 
 
2.2(a) In vitro cytotoxicity of NSCLC model 
 
In vitro cytotoxicity of POx formulations on the 344SQ LUAD cell line was assessed by 
studying the cell viability following treatment with various concentrations of free drugs and 
polymeric formulations of C6CP, PTX, AZD7762, VE-822, AZD8055, C6CP/AZD7762, C6CP/VE- 
822, C6CP/AZD8055, PTX/VE-822, and Resiquimod, prepared by serial dilution in full medium. 
The 344SQ cell line was provided by J. Kurie (MD Anderson Cancer Center, Houston, TX). 
The cells were cultured in RPMI (Gibco) medium supplemented with 10% fetal bovine serum 
(FBS) and 1% penicillin-streptomycin at 37°C with 5% CO2. Five thousand cells per well were 
seeded in 96-well plates and allowed to attach for 24 hours before treatment. Seventy-two 
hours following drug treatment, cell viability was measured by the Dojindo Cell Counting Kit-8 
(CCK-8) using the manufacturer’s protocol. The IC50 was calculated using the GraphPad 
Prism 6 software. Quantification of the synergistic effect of drug combinations was done using 
CompuSyn software based on the CI theorem of Chou and Talalay. 
2.3(b) In vitro cytotoxicity of TNBC Model 
 
In vitro cytotoxicity of POx formulations on the 4T1 TNBC-like cell line was assessed by 
studying the cell viability following treatment with various concentrations of free drugs and 
polymeric formulations of PTX, SB525334, LY2109761, SB505124, PTX/SB525334, 
PTX/LY2109761, and PTX/SB525334, prepared by serial dilution in full medium. The 4T1 cell 
line was obtained from UNC Tissue Culture Facility. 4T1 cells were cultivated with RPMI 
(Gibco) 1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic- 
antimycotic at 37 °C and 5% CO2. Five thousand cells per well were seeded in 96-well plates 
and allowed to attach for 24 hours before treatment. Seventy-two hours following drug 
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treatment, cell viability was measured by the Dojindo Cell Counting Kit-8 (CCK-8) using the 
manufacturer’s protocol. The IC50 was calculated using the GraphPad Prism 6 software. 
Quantification of the synergistic effect of drug combinations was done using CompuSyn 
software based on the CI theorem of Chou and Talalay. 
2.3 In vitro activation of BMDMs 
 
BMDMs were derived from the femur bone marrow of FVB/NJ mice per previously 
published protocol27. Briefly, bone marrow cells were extracted from the bone marrow of 6- to 8- 
week-old mice and subjected to red blood lysis by ACK (ammonium-chloride-potassium) lysing 
buffer. The resulting cell suspension was maintained in Dulbecco’s modified Eagle’s medium 
supplemented with 10% FBS, 1% penicillin-streptomycin, and recombinant murine macrophage 
colony-stimulating factor (M-CSF) (10 ng/ml) for 10 days. On day 11, the medium was replaced 
with CSF-free medium, and on the following day, the cells were treated with free and micelle- 
incorporated Resiquimod. For analysis of the in vitro polarization status of macrophages, total 
RNA was harvested from BMDM 4 hours after treatment per Qiagen RNA extraction protocol 
(Qiagen). RNA was then reverse transcribed to complementary DNA (cDNA) using an iScript Kit 
(Bio-Rad). Using cDNA as a template, the gene expression of the Tnfa, il1b, il6, nos2, cmyc, 
il10, and mrc2 was measured by quantitative polymerase chain reaction (PCR) (relative to 
18S) on QuantStudio 6 Flex Real-time PCR system (Applied Biosystems). 
2.4 Estimation of MTD 
 
A dose-escalation study was used to identify the highest safe dose (MTD). Tumor-free 
female 8-week-old 129/Sv mice were segregated into groups of three, with each group subjected 
to increasing doses of drugs. Resiquimod PM (1, 3, and 5 mg/kg), C6CP/AZD7762 PM (2.5/5, 
5/10, 10/20 mg/kg), and C6CP/VE-822 PM (10/10, 7.5/7.5, and 5/5 mg/kg) and normal saline 
(control) were injected intra- venously following q4d × 4 regimen. Every mouse was assigned a 
unique ID. Body weight loss of 15% or greater and other signs of toxicity such as hunched 
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posture and rough coat were set as the study endpoints. The mice were monitored every other 
day until the end of the study. 
2.5 Animal tumor models 
 
Animal studies were conducted in accordance with the University of North Carolina at 
Chapel Hill Institutional Animal Care and Use Committee guidelines. 
2.5(a) 344SQ animal tumor model of NSCLC 
 
344SQ murine LUAD cells expressing firefly luciferase and green fluorescent protein [in 
50 μL of 1:1 mix of Hanks’ balanced salt solution (HBSS) and BD Matrigel] were injected into the 
left lung of 8-week-old female 129/Sv mice via intrapulmonary injection as described 
previously28. Briefly, mice anesthetized with ketamine + xylazine + acepromazine were laid in 
lateral decubitus position, and an incision was made between ribs 10 and 11 to visualize and 
access the lung. The cell suspension was directly injected into the lung parenchyma at the 
lateral dorsal axillary line, following which the incision was closed using surgical clips. The 
animals were monitored until full recovery. 
2.5(a) 4T1 animal tumor model of TNBC 
 
4T1 murine TNBC-like cells expressing firefly luciferase and green fluorescent protein 
were injected into one mammary fat pad of 8-week old female Balb/c mice via intrapulmonary 
injection as described previously29. Briefly, mice were laid in supine decubitus position, and the 
cell suspension was injected directly into the 4th left inguinal mammary gland fat pad. The 
animals were monitored until full recovery. 
2.6 In vivo efficacy study 
 
2.6(a) Chemotherapy in conjunction with chemosensitizers 
 
344SQ–green fluorescent protein (GFP)/fLuc cells (2.5 × 103) were orthotopically 
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injected in the left lung of 8-week-old 129/Sv mice. Treatments were commenced a week after 
tumor inoculation. Baseline bioluminescence was measured using IVIS lumina optical imaging 
system before treatment administration. Mice randomized into groups of 10 received 
intravenous injections (i) normal saline, (ii) C6CP/AZD7762 PM (10/20 mg/kg), and (iii) 
C6CP/VE-822 PM (10/10 mg/kg), and intraperitoneal injection of anti–PD-1 antibody (250 μg 
per mouse) using q4d × 4 regimen. Mouse survival and body weight changes were monitored 
every other day. Tumor load was measured weekly by bioluminescence imaging. Mice 
exhibiting signs of distress such as labored breathing, restricted mobility, ruffled fur, hunched 
posture, weight loss of greater than 15%, and moribund state were euthanized by carbon 
dioxide intoxication, followed by cervical dislocation. 
2.6(b) TLR Immunotherapy alone and in combination with immune checkpoint 
blockade 
A week after tumor inoculation (5 × 103 344SQ-GFP/fLuc cells in 50 μL of 1:1 mix of 
HBSS and BD Matrigel), the animals (n = 13) received the following injections: (i) normal saline 
(q4d × 4 doses, iv), (ii) Resiquimod PM (5 mg/kg; q4d × 4 doses, iv), (iii) anti–PD-1 [250 μg per 
mouse; q4d, intraperitoneally (ip)], and (iv) Resiquimod PM (5 mg/kg; q4d × 4 doses, iv) + anti– 
PD-1 (250 μg per mouse; q4d, ip). A total of four doses were administered for Resiquimod PM, 
whereas anti–PD-1 was continued throughout the duration of the experiment. For the 
combination treatment, Resiquimod PM and anti–PD-1 were administered on the same day for 
a total of four doses, after which anti–PD-1 was continued for an additional four doses (without 
Resiquimod). 
2.7 Evaluation of tumor microenvironment modulation by POx/Resiquimod 
 
Subcutaneous 344SQ LUAD (105 44SQ-GFP/fLuc cells) tumors were formed in 8-week-old 
129/Sv mice. The mice were then randomly split into treatment arm [Resiquimod PM (5 mg/kg); 
n = 8] and control arm (normal saline; n = 8). Each group received two intravenous injections of 
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the respective treatments on days 8 and 11 after tumor inoculation. 
 
2.7(a) Flow Cytometry 
 
For examining the immune status of the tumors after treatment, the subcutaneous tumors were 
resected 48 hours after the second treatment. The harvested tumors were subjected to enzyme 
treatment [collagenase 2 mg/ml in HBSS; dispase 2.5 U/ml in HBSS; deoxyribonuclease 1 mg/ml 
in phosphate-buffered saline (PBS)] for an hour at 37°C while shaking and digested into a single- 
cell suspension. The cell suspension was then passed through a 40-μm cell strainer. After the 
removal of red blood cells by ACK lysis buffer, the cells were resuspended in fluorescence- 
activated cell sorting (FACS) buffer (500 ml of 1× PBS without Ca2+ or Mg2+ + 2mM EDTA + 2% 
FBS) and counted for downstream staining. Live cells (1 × 106) were stained with Zombie Violet 
live/dead stain (BioLegend) as per the supplier’s recommendations, and excess live/dead stain 
was removed by washing cells twice and resuspending in 50 μL of FACS buffer. Next, cells were 
incubated with 1 μg of anti-mouse CD16/CD32 (TruStain FcX; BioLegend) on ice for 15 min. The 
cells were then mixed with 50 μL of mixture of various fluorescently labeled monoclonal 
antibodies against murine cell surface markers and incubated for 30 min on ice in the dark. Lastly, 
cells were rinsed, resuspended in 300 μL of FACS buffer, and was immediately fluorescence 
activated on LSRII (BD; FACSDiva 8.0.1 software) at the UNC (University of North Carolina) 
Flow Cytometry Facility. Data were acquired with forward (FSC) and side (SSC) scatter on a 
linear scale, while fluorescent signals were collected on a five-decade log scale with a minimum 
of 100,000 events per sample. Nonstained harvested cells were used as universal negative 
control. Compensation beads (Thermo Fisher) were used for single color control samples. 
Harvested spleen cells were used as positive controls for immune cell staining. Analysis of flow 
cytometry data was performed using FCS Express (DeNovo Software). All antibodies were 
purchased from BioLegend. 
2.7(b) Measurement of serum cytokines/chemokines 
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Analysis of serum cytokines/chemokines was performed using a high-sensitivity immunology 






3.1 Characterization of POx formulations 
 
 
3.1(a) Coformulation of chemosensitizers and anticancer agent 
 
 
Cisplatin is a standard of care for advanced NSCLC (16). Additionally, while it is not 
currently the standard of care for TNBC, there is renewed interest in cisplatin formulations as 
treatment options30. However, the initial response to cisplatin is often short-lived because of the 
development of drug resistance31. We hypothesized that cancer cells could be sensitized to 
chemotherapy by using chemosensitizers, which are agents that harbor the potential to reverse 
drug resistance32. Three different chemosensitizers were evaluated for coformulation with the 
alkylated prodrug of cisplatin (C6CP): (i) AZD7762—a chemosensitizer that can inhibit the DNA 
repair activity by check- point kinases following treatment with DNA-damaging agents such as 
cisplatin and, thus, improve the therapeutic margin of chemo- therapy33; (ii) VE-822—an 
inhibitor of ataxia telangiectasia and Rad3-related (ATR), a DNA damage response pathway 
that is exploited by cancer cells as a rescue strategy for DNA damage34; and (iii) AZD8055—an 
inhibitor of the mammalian target of rapamycin (mTOR) kinase. mTOR is a serine/threonine 
kinase involved in the regulation of cell growth and autophagy35. Mutation in the mTOR pathway 
is common in NSCLC, making it a suitable choice of a chemosensitizer36. 
 
The hydrophobic nature of C6CP favored the easy incorporation of cisplatin into the 
hydrophobic micelle core. C6CP/chemosensitizer coloaded micelles were formulated at 
different feeding ratios of the two drugs. Four ratios (w/w) of C6CP/chemosensitizer (4/8, 6/6, 
8/4, and 
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9/3) were screened, keeping the polymer quantity fixed. A maximum loading capacity as high as 
45 weight % was obtained with the C6CP/AZD7762 coloaded micelles at a loading ratio of 2/6 
(feeding ratio of 4/8). C6CP/VE-822 coloaded micelles exhibited high loading efficiency (70 to 
90%) and high loading capacity (≥49%) for all the ratios tested (Table 1). In addition, the 
C6CP/AZD8055 co-loaded micelles also displayed a high loading capacity of more than 50% for 
three of the four ratios tested. Micelle sizes varied with the feeding ratios, ranging from 25 to 
354 nm. 
 
Paclitaxel (PTX) was selected as the second chemotherapeutic candidate for 
combination with the chemosensitizer since the POx micellar formulation of PTX has been 
extensively studied and shown to have a drug loading capacity superior to clinically approved 
Abraxane, resulting in improved anticancer efficacy when ad- ministered at the maximum 
tolerated dose (MTD) of the respective formulations23. The PTX/VE-822 combination exhibited a 
high loading capacity of more than 48% for all the four ratios tested. 
 
3.1(b) Resiquimod PM 
 
Resiquimod is an imidazoquinoline immune response modifier that stimulates TLR 7 in 
mice and TLR 7/8 in humans21. We sought to formulate Resiquimod in POx micelles to improve 
the aqueous solubility of Resiquimod for intravenous delivery in mice. By keeping the polymer 
amount constant and incrementally increasing the drug amount, different feeding ratios of 
Resiquimod were examined. Resiquimod was well solubilized even at a high feeding ratio of 
8/10, yielding a drug concentration of 7 mg/ml in saline and a loading capacity of 41% by 
weight. The size distribution obtained from dynamic light scattering (DLS) indicated the 
presence of small and monodisperse particles for feeding ratios 2/10 to 8/10 (Fig. 1, A and D). 
This was corroborated by transmission electron microscopy (TEM), which showed small and 
spherical particles of about 20 nm in size (Fig. 1, B and  C).
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Table 1 | Characterization of POx micelles co-loaded with anticancer agent and chemosensitizers   
Checkpoint kinase inhibitor (AZD7762) and anticancer agent (C6CP)  
Feeding ratio  
(g/L)  
C6CP/AZD7762/POx  
LE (%)  LC (%)  Drug concentration in 
solution (g/L)  Deff (nm)  PDI  
C6CP  AZD7762  C6CP  AZD7762  Tot  C6CP  AZD7762  
8/0/10  71.3  -  36.3  -  -  5.7  -  124 ± 0.5  0.05 ± 0.05  
0/8/10  -  73.8  -  37.1  -  -  5.9  64 ± 3.6  0.64 ± 0.02  
4/8/10  52.5  77.5  11.5  33.9  45.4  2.1  6.2  25 ± 0.8  0.42 ± 0.02  
6/6/10  40.0  70.0  14.5  25.3  39.8  2.4  4.2  82 ± 4.7  0.45 ± 0.07  
8/4/10  38.8  80.0  19.0  19.6  38.6  3.1  3.2  128 ± 0.7  0.09 ± 0.02  
9/3/10  58.9  90.0  29.4  15.0  44.4  5.3  2.7  112 ± 1.1  0.09 ± 0.02  
ATR inhibitor (VE-822) and anticancer agent (C6CP)  
Feeding ratio  
(g/L)  
C6CP/VE-822/POx  
LE (%)  LC (%)  Drug concentration in 
solution (g/L)  
Deff (nm)  PDI  
C6CP  
VE-
 822  C6CP  
VE-
 822  Tot  C6CP  VE-822  
8/0/10  98.8  -  44.0  -  -  7.9  -  122 ± 0.9  0.10 ± 0.03  
0/8/10  -  83.8  -  40.0  -  -  6.7  351 ± 6.7  0.40 ± 0.08  
4/8/10  92.5  75.0  18.8  30.5  49.3  3.7  6.0  354 ± 4.7  0.50 ± 0.02  
6/6/10  91.7  83.3  26.8  24.4  51.2  5.5  5.0  240 ± 1.9  0.30 ± 0.01  
8/4/10  96.3  85.0  36.5  16.1  52.6  7.7  3.4  211 ± 3.8  0.30 ± 0.02  
9/3/10  91  90.0  39.2  13.0  52.2  8.2  2.7  160 ± 2.4  0.20 ± 0.01  
 
Table 1. Characterization of POx micelles coloaded with anticancer agent and chemosensitizers. Characterization of 
POx micelles coloaded with anticancer agent and chemosensitizers. LE, loading efficiency; LC, loading capacity; PDI, 
polydispersity index. 
 






Fig. 1. Physical characterization of Resiquimod PM (a) Particle size distribution of Resiquimod PM at 
different feeding ratios as a function of intensity (percent), measured by dynamic light scattering; (b, c) 
Transmission electron micrographs at different magnifications show the spherical morphology of Resiquimod 
PM particles (4/10 g/L) and illustrate the uniformity of particle shape and size; (d) Characterization of POx 
micelles loaded with TLR 7/8 agonist (Resiquimod). 
 
3.2 In vitro cytotoxicity 
 
 
Anticancer agents (C6CP and PTX) and chemosensitizers (AZD7762, VE-822, and 
AZD8055) alone or in combination were tested for their in vitro cytotoxicity in the 344SQ lung 
adenocarcinoma (LUAD) cell line. For the single-agent polymeric micelle controls, the drugs 
were tested in fivefold increments at concentrations ranging from 0.256 ng/ml to 100 µg/ml 
(equivalent to 0.5 nM to 188 µM for C6CP PM, 0.3 nM to 117 µM for PTX PM, 0.7 nM to 275 µM 
for AZD7762 PM, 0.5 nM to 215 µM for VE-822 PM, and 0.5 nM to 215 µM for AZD8055 PM). 
To investigate the effect of drug ratios on synergy, we tested four anticancer 
agent/chemosensitizer ratios (w/w) at combined concentrations of both drugs ranging from 
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0.256 ng/ml to 100 µg/ml. In addition, we also studied the effects of free drugs and their 
mixtures. The limited solubility of drugs in the absence of micelles in the cell culture medium 
was factored in the selection of dose range for free drugs (0.0256 ng/ml to 10 µg/ml). 
 
A dose-dependent decline in cell viability was observed in all treatments involving C6CP. 
The IC50 (half-maximal inhibitory concentration) values revealed that the two-drug–loaded 
micelles of C6CP were generally more potent than either of the drugs used alone. Furthermore, 
with the exception of C6CP, the IC50 values of polymeric micelle encapsulated drugs were 
substantially lower than those of free drugs when compared at the same concentration range 
(Fig. 2, A, B, D, E, and G). This was also true for the mixture of two free drugs, which displayed 
a higher IC50 value than two-drug–loaded micelles of the same ratio. In marked contrast, PTX 
had minimal cytotoxic effect on this cell line. Previous research has shown that increased 
exposure time in conjunction with increased dose improved the cytotoxicity of PTX 37; however, 
following exposure to PTX for 72 hours, the cytotoxicity of PTX was found to be modest in the 
present study. Nonetheless, the combination of PTX and VE-822 resulted in considerably higher 
cytotoxicity due to the chemosensitizing activity of VE-822. The synergy of different drug 
combination ratios was studied using the combination index (CI) theorem (isobologram 
equation) of Chou and Talalay, which states that a CI value of less than 1 represents 
synergy, whereas a CI value greater than 1 indicates antagonism26. It should be noted 
that the superadditive therapeutic effect of drug combinations is strongly influenced by 
the drug ratios24. Every feed ratio (4/8 to 9/3) of the C6CP/AZD7762 combination 
yielded CI < 0.3 for cell death fraction (Fa: fraction affected) ranging from 0.1 to 0.9, 
suggesting a strong synergy of cotreatment. C6CP/VE-822 drug pair, too, depicted 
synergy for all feed ratios (CI < 1) with pronounced synergy (CI < 0.5) at the C6CP/VE- 
822 feed ratio of 4/8 (Fig. 2, C and F). Furthermore, C6CP/AZD8055 pair displayed 
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maximum synergy at a feed ratio of 6:6, and while PTX/ VE-822 showed synergistic 
effect at all feed ratios, maximum synergy was observed for the feed ratios of 8/4 and 
9/3. Because of the superior toxicity profile and synergistic effect of C6CP/ AZD7762 
and C6CP/VE-822 combinations, they were identified as lead candidates for in vivo 
study. Resiquimod, on the other hand, did not exhibit any cytotoxic activity in 344SQ 
cells at concentrations ranging from 0.00128 to 20 µg/ml. This observation is consistent 
with previous works that report Resiquimod as lacking a direct antineoplastic effect. 
However, its analog, imiquimod, has been shown to have a proapoptotic effect on a 
human skin cancer cell line. The distinct effects of the two TLR agonists were 
speculated to be due to the disparate subcellular localizations of the two compounds38. 






Fig. 2. In vitro cytotoxicity of anticancer agent and chemosensitizers in 344SQ lung adenocarcinoma 
cell line (a, b, d, e). Dose-response curves of free and micelle incorporated drugs and drug combinations in 344SQ 
cell line after 72h of treatment. Cell viability as a function of individual drug concentrations after treatment with a 
combination of the drugs AZD8055 and C6CP (A and B) and VE-822 and PTX (D and E). The data were fit into 
sigmoidal curve using nonlinear regression. Data represent mean ± CV. n = 6. (C and F) Fa-CI plots of the 
C6CP/AZD7762 and C6CP/VE-822 combinations. Data represent means. n = 6. (G) Comparison of the IC50 values 
of POx formulations and free drugs in the 344SQ cell line 
 
 
3.3 Characterization of Resiquimod-mediated BMDM activation in vitro 
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Macrophages account for a major percentage of tumor-infiltrating leukocytes13. 
 
Because of their plastic nature, TAMs are prime targets of cancer-mediated 
“reprogramming” to a tolerogenic (TH1/ TH2 low) phenotype. Immunotherapeutic 
strategies aimed at resetting the TH1/TH2 ratio to restore the tumoricidal function of 
macrophages have shown promise in treating cancer39. Accordingly, we sought to 
investigate the potential of Resiquimod PM to polarize murine bone marrow–derived 
macrophages (BMDMs) to an antitumor phenotype (TH1/TH2 high) via TLR stimulation. 
As shown previously, Resiquimod was found to lack cytotoxic effect on macrophages at 
the concentration used for the experiment40. Resiquimod PM and free Resiquimod 
treatment of BMDM resulted in an increase in the mRNA expression of tumor necrosis 
factor– (TNF-), interleukin-1 beta (IL-1), IL-6, and nitric oxide synthase-2 (NOS2) 
(classical activation) in a manner similar to that of LPS (lipopolysaccharide), a TLR 4 
agonist (Fig. 3A). IL-1 is an important TH1 cytokine that promotes anticancer immune 
response by activating and expanding CD4 and CD8 T effector cells41. IL-6 signaling is 
again pivotal to the differentiation of T and B cells42. The antitumor activity of 
macrophages ensues partly from NOS2 expression. NOS2 encodes inducible nitric 
oxide synthase (iNOS), an enzyme that catalyzes the production of tumoricidal reactive 
oxygen species (8). While the expression levels of IL-6, IL-1, and NOS2 for the 
Resiquimod and LPS treatment groups were considerably enhanced, TNF- expression 
was relatively modest. This could be due to the 4-hour time frame as the expression of 
TNF- is reportedly low at early time points following macrophage stimulation38. 
Analysis of alternatively activated macrophage markers showed a low expression of the 
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c-myc gene. However, treatment with Resiquimod and LPS elicited an increased 
expression of IL-10 (Fig. 3B). 
 
This was not unexpected because IL-10 protein expression is known to 
counterbalance the production of TNF-, resulting in a low TNF-/IL-10 ratio. The 
increase in TNF- expression over time is expected to thwart the production of IL-10. 
Furthermore, POx (vehicle) was found to stimulate the expression of IL-1b, IL-6, and 
NOS2 in BMDM, albeit to a much lower extent than Resiquimod and LPS treatments 
(Fig. 3A). This observation is consistent with a study by Hou-Nan Wu and co-workers 
that looked at macrophage stimulation by amphiphilic polymers, where polymeric 
micelles induced the production of TNF- and MCP-1 from macrophages in a time- 
dependent manner. However, following treatment of mice with these micelles, 
inflammatory mediators were not detected in the plasma of these animals43. Therefore, 
we believe that the macrophage stimulation effect of POx micelles is not strong enough 
to warrant further investigation. Following treatment with Resiquimod PM and 
Resiquimod, cell morphology of BMDM shifted from elongated structures in resting 
macrophages (saline- and POx treated groups) to round and flattened structures, 
characteristic of TH1-activated macrophages (Fig. 3C)44. 







Fig. 3 In-vitro activation of BMDM. (a) Relative mRNA expression of M1-like macrophage markers 
(TNFa, IL-1b, IL-6, NOS2) normalized to 18s (b) Relative mRNA expression of M2-like macrophage markers 
(cMYC, IL-10) normalized to 18s. Data represent mean ± SEM. n = 3. **p < 0.01, ***p < 0.001 computed by unpaired 
student t test with Welch’s correction. Significance level (α) was set at 0.05. (c) Cell morphology of resting macrophages 
and M1 polarized macrophages following Resiquimod and Resiquimod PM (2/10 g/L) treatments (bottom). Scale bar 
= 50 µm. 
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3.4 Estimation of MTD 
 
We have previously demonstrated the hematological and immunological safety of 
POx by the assessment of liver and kidney function (blood chemistry panel), 
complement activation, and histopathology of major organs following repeated 
intravenous injections (q4d × 4) in mice23. Therefore, no further toxicity analysis was 
performed for the polymer alone in this study. Dose-escalation study of single agent 
POx micelles of C6CP, AZD7762, and VE-822 in 129/Sv mice served as a basis for the 
determination of doses for the combinations. For both combinations, all three doses 
tested (2.5/5, 5/10, and 10/20 mg/kg and 10/10, 7.5/7.5, and 5/5 mg/kg for C6CP/ 
AZD7762 PM and C6CP/VE-822 PM, respectively) were well tolerated by the mice. 
There was no incidence of death. Even at the highest tested dose, mice body weight did 
not fall below 5% of initial weight. Furthermore, no obvious behavioral abnormalities 
were observed in these mice. Accordingly, C6CP (10 mg/kg) and AZD7762 (20 mg/kg) 
for C6CP/AZD7762 and C6CP (10 mg/kg) and VE-822 (10 mg/kg) for C6CP/VE-822 
were established as the no observed adverse effect level (NOAEL). 
 
MTD finding studies for cancer immunotherapy are confounding because, unlike 
chemotherapy, higher doses do not necessarily increase efficacy. The nonlinear dose- 
efficacy relationship of immune response modifiers makes it challenging to establish an 
MTD for these molecules. For this reason, most clinical studies involving 
immunomodulatory agents use doses below MTD45. As for Resiquimod PM, all three 
tested doses were well tolerated by the mice, as evidenced by the absence of any 
clinical signs. The body weight changes of the Resiquimod PM–treated group had a 
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similar trend to that of the control group. Thus, 5 mg/kg was identified as a safe dose for 
the in vivo efficacy study. 
 
3.5 Tumor inhibition study 
 
We evaluated the antitumor efficacy of platinum-based chemotherapy in 
combination with chemosensitizers, and Resiquimod PM alone and in combination with 
anti–PD-1 in an immune-competent, orthotopic model of LUAD, prepared from the 
344SQ LUAD cell line derived from the metastases of the genetically engineered mouse 
model of LUAD carrying KrasG12D and p53R172HG mutations. The ability to produce 
spontaneous metastases and, thus, recapitulate the pathophysiology of LUAD is the key 
strength of this model46. The lack of any anticancer activity of POx alone has been 
previously demonstrated in this model26. Unexpectedly, neither of the combination drug 
PMs (C6CP/AZD7762 PM and C6CP/VE-822 PM) improved survival relative to the 
control group despite having a strong synergistic effect in vitro. The median survival was 
24 days for C6CP/AZD7762 PM and 28 days for C6CP/VE-822, which was comparable 
to the untreated group. Furthermore, the anti–PD-1 treatment produced a modest 
improvement in survival, relative to the control (Fig. 4A). 
Resiquimod PM monotherapy resulted in a pronounced increase in overall 
survival (Fig. 4B). The median survival was 57 days for this group, which was a 
significant improvement given the poor prognosis of this model of NSCLC. Luciferase 
expression of the 344SQ cell line allowed the assessment of tumor growth by 
bioluminescence imaging. The dose of Resiquimod PM was terminated on day 19 to 
assess the durability of the anticancer immune response. Despite lacking a direct 
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anticancer effect, Resiquimod PM treatment substantially suppressed tumor 
progression for over 20 days following the cessation of treatment (Fig. 4, C and D). 
Anti–PD-1 monotherapy provided a modest benefit to tumor growth. Although the 
combination of anti–PD-1 and Resiquimod PM performed better than anti–PD-1 alone, it 
did not provide any discernible benefit over Resiquimod PM monotherapy. A possible 
explanation for the lack of synergy between anti–PD-1 and Resiquimod PM is the 
development of resistance to anti–PD-1 over time due to the selection pressure on 
cancer cells, which drives new mutations to enable mechanisms that can suppress host 
immunity independently of PD-L147. Chen et al. 48 have recently confirmed this by 
showing up-regulation of CD38 (an ectozyme shown to mediate suppression of T 
lymphocytes) as a mechanism for acquired resistance to anti– PD-1 in two separate 
lung cancer models, notably one of which included the 344SQ model. Last, the body 
weights of the mice from the Resiquimod PM and combination groups remained 
consistent when compared with mice from the saline and anti–PD-1 groups, indicating 
better health status. 






Fig. 4 Tumor inhibition in 344SQ Lung Adenocarcinoma bearing mice Kaplan-Meier survival plots of 
 
(a) tumor bearing mice treated with four i.v. injections of Saline, C6CP/AZD7762 PM, and C6CP/VE-822 PM (b) 
tumor bearing mice treated with four i.v. injections of Saline, Resiquimod PM, 8 i.p. injections of anti-PD1 antibody, 
and a combination of Resiquimod PM (4 i.v. injections) anti-PD1 antibody (8 i.p. injections), p values were computed 
Sloane Fussell 27 
 
by Log-rank (Mantel-cox) test. Significance level (α) was set at 0.05. (c) Quantification of BLI signal; data represent 
mean ± SEM. n = 13. (d) Representative IVIS images of mice from each treatment group on the days of the treatment. 
 
3.6 Resiquimod controls LUAD growth by mediating host immune response 
 
To uncover the immunomodulatory effect of Resiquimod cargo, we analyzed the 
immune status of the tumor microenvironment by flow cytometry at 48 hours after the 
second injection of Resiquimod PM in LUAD-bearing mice. Given the vital role of 
macrophages in regulating the inflammatory response, we sought to examine its surface 
profile following TLR stimulation. Tumors that received Resiquimod PM treatment 
showed an increased incidence of CD11b+ / CD11c− /Ly6C+ monocytes (Fig. 5). 
Ly6C+ monocytes are prone to differentiate into inflammatory macrophages and secrete 
TH1 cytokines that activate adaptive immune response49. We next investigated the 
influence of Resiquimod treatment on dendritic cells. The CD11b+ /CD11c+ expressing 
dendritic cell subset was found to be reduced in the treatment group compared with the 
control. This observation was consistent with the finding by Decker and co-workers50 
that the CD11c marker is down-regulated upon activation of mouse dendritic cells by 
TLR stimulation. Accordingly, it is reasonable to conclude that dendritic cell activation by 
Resiquimod PM led to the down-regulation of the CD11c marker, yielding a low number 
of CD11c+ cells in the tumor. Last, we examined whether the stimulation of antigen- 
presenting cells (APCs) led to the induction of T cell response. Flow analysis of cells 
triple-stained for CD45+ / CD3+ /CD4+ and CD45+ /CD3+ /CD8+ revealed an increase 
in the CD8+ T cell population and an upward trend in CD4+ T cell population in the 
tumors of the treatment group, suggesting the ability of Resiquimod monotherapy to not 
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only mount tumor-specific immune response by CD8+ T cells but also activate the 
CD4+ T cell population, required for the generation of memory immune response51. 
Next, we looked at serum cytokine/chemokine levels in tumor bearing mice to 
assess the systemic inflammatory status at 48 hours following the second injection of 
Resiquimod PM. Serum titers of proinflammatory cytokines or chemokines in the 
Resiquimod PM– treated group did not differ significantly from the saline group. This 
was not unexpected as previous studies have shown that proinflammatory cytokines 
return to baseline levels approximately 24 hours after TLR agonist dosing in normal 
mice52,53. Downmodulation of systemic cytokine signaling is a widely accepted 
mechanism of immune system regulation involving the SOCS (suppressor of cytokine 
signaling) family of proteins to keep immune disorders caused by constitutive 
expression of proinflammatory proteins in check54. 






Fig. 5 Resiquimod PM induces Th1 polarization of immune cells in the TME. a) Representative FACS plots of 
CD11b+/CD11c-/Ly6C+, CD45+/CD3+/CD4+ and CD45+/CD3+/CD8+ cell population from the tumors of mice treated 
with saline and Resiquimod PM. b,c,d,e,) Quantification of indicated population of cells. Data represent mean ± 





Our animal model of LUAD is developed by orthotopic injection of the Kras/p53 
cell line (344SQ) into the lung of a syngeneic, immunecompetent host. The 344SQ cell 
line is predisposed to metastasis because of loss of miR-200 family, a negative 
regulator of epithelialto-mesenchymal transition, and, thus, metastasis55. Metastatic 
LUADs harboring Kras/p53 mutations are associated with considerably lower numbers 
of tumor-infiltrating CD8+ T cells8. Insufficient numbers of tumor-infiltrating T cells 
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preclude response to immunotherapeutic strategies such as anti–PD-1 therapy that 
primarily act on preexisting anticancer T cells56. While this may explain the innate 
resistance to anti–PD-1 therapy, acquired resistance to anti–PD-1 is a consequence of 
evolutionary pressure on cancer cells, resulting in PD-L1–independent mechanisms of 
immune evasion48,57. An alternative approach is, therefore, necessary to treat tumors 
refractory to anti–PD-1. 
 
Resiquimod is 100 times more potent (on a weight basis) as an immune 
response modifier than imiquimod. However, clinical trials involving topical Resiquimod 
have shown limited success owing to the poor systemic absorption (<1%) of local dose, 
resulting in suboptimal serum levels of Resiquimod21,58. Here, we report that our novel 
POx-based nanomicellar formulation of Resiquimod provides an apposite platform for 
the systemic administration of the TLR agonist. Resiquimod PM not only was well 
tolerated by mice at a dose of 5 mg/kg [intravenously (iv)] but also extended the overall 
survival in LUAD-bearing mice, outperforming anti–PD-1 therapy. In contrast, despite 
exhibiting an excellent in vitro synergistic anticancer effect, chemosensitizers and 
anticancer drugs coformulated in POx micelles did not display a therapeutic effect in 
LUAD mice compared with the control group, underscoring the insensitivity of the LUAD 
model to chemotherapeutic strategies. 
 
While lacking a direct antitumor effect, Resiquimod functions by orchestrating the 
immunomodulation of the tumor microenvironment, resulting in the mobilization of the 
antitumor immune response59. Immunogenicity of Resiquimod is conferred by its close 
resemblance to purine bases found in RNA, which are natural ligands of TLR21. 
Because TLR 7/8 are principally located intracellularly21, encapsulation of Resiquimod in 
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POx micelles is particularly beneficial for easy access to endosomally located TLR 7/8 
following endocytic internalization of Resiquimod PM by immune cells. The association 
of Resiquimod and TLR 7/8 initiates the MyD88 (myeloid differentiation primary 
response 88)–dependent signaling cascade, culminating in the TH1 immune response. 
MyD88 is an important adaptor protein that mediates the association between TLRs and 
IL-1R–associated kinases (IRAKs) and thereby triggers the activation of mitogen- 
activated protein kinases (MAPKs) and IB kinase (IKK) complex, ultimately leading to 
the nuclear translocation and transcription of nuclear factor B (NFB) and subsequent 
induction of TH1 cytokines and chemokines21,60,61. TH1 cytokine signaling potentiates 
the immune response against cancer and recruits more cells of the TH1-high endotype. 
Most notably, TH1 priming enhances the phagocytic activity of APCs and up-regulates 
the expression of major histocompatibility complex (MHC) and costimulatory molecules, 
resulting in the rapid phagocytosis of tumor cells and presentation of the tumor antigen 
to T cells in tumor-draining lymph node (TDLN), a prerequisite for the generation of 
tumor-specific immune response18. Our results indicate that Resiquimod PM can 
effectively polarize APCs (both macrophages and dendritic cells) to an antitumor 
phenotype in vivo in the LUAD tumor model, corroborating our in-vitro study with 
BMDM, and concomitantly increase the infiltration of CD8+ T cells in the tumors, 
substantiating the potency of Resiquimod PM in generating a CTL response. 
It is understood that the success of immunotherapy hinges on its ability to 
potentiate the immune response to cancer by acting at the right location at the right 
time. While POx nanoformulation of Resiquimod addresses the former requisite, the 
latter can be addressed by using a dosing strategy that synergizes with the natural 
Sloane Fussell 32 
 
timing of the immune response. From the recognition of tumor antigen to the infiltration 
of antitumor T cells, the development of immune response follows a coordinated 
sequence of events lasting several days62. Accordingly, the dosing schedule in 
immunotherapy should be optimized to allow sufficient time for maximum APC–T cell 
interaction. The limitation of this study is that we do not know whether the dosing 
regimen chosen for the study is optimal. This will be investigated in the future with the 
help of suitable biomarkers that can offer a peek at the windows of opportunity for 
assessing the ideal time frame for dosing to amplify the therapeutic efficacy of 
immunotherapy. 
 
Despite a promising therapeutic profile, toxicity resulting from hyperstimulation of 
the immune system (also known as cytokine storm) is a major bottleneck to clinical 
translation of TLR agonists63. Clinical manifestations of cytokine storm range from mild 
(flu-like disease that is easily managed) to severe (rare but potentially life-threatening)64. 
Owing to the fundamental differences in the innate immunity between mice and 
humans, mice do not exhibit clinical signs of cytokine storm and, therefore, may have a 
poor predictive value for the human disease64,65. Therefore, our mouse model does not 
allow the study of toxicities resulting from cytokine storm. Nonetheless, research on the 
management of the cytokine storm has demonstrated that it can be managed by 
blocking specific cytokines without compromising efficacy66. A recent study by Norelli 
et al.67 showed both IL-1 and IL-6 (implicated as a key driver of cytokine storm) were 
involved in the pathogenesis of cytokine storm in a humanized mouse model of 
leukemia, and because IL-1 signaling preceded IL-6, the blockade of IL-1 receptor was 
shown to successfully overcome the toxicities associated with the syndrome. Future 
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studies will work to address the TME of more desmoplastic tumors, such as the 
previously mentioned TNBC, through the targeting of CAFs. One possible treatment 
option, the TGFβR1 inhibitor SB525334, has already been selected as a possible option 
to inhibit various growth factors of tumor associated fibroblast cells. 
 
In summary, this study highlights the preeminent tumor inhibition activity of 
Resiquimod PM brought about by effective immunomodulation of the tumor 
microenvironment and its potential to serve as an alternative to treatments that do not 
work on immunologically cold tumors. Although the investigation of the antitumor 
memory response was beyond the scope of this study, it is well recognized that 
activation and deployment of the adaptive immune surveillance generate long-term 
immunological memory that can counter cancer recurrence68. 
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